VRDN Earnings Date: Nov 4, 2026 (Estimated) — Viridian Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology
Updated
When is VRDN's next earnings date?
Viridian Therapeutics, Inc. (VRDN) is expected to report Q3 2026 earnings on Wednesday, November 4, 2026 at 7:00 AM ET (before market open); the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of -$1.02 on revenue of $4.7M.
How did VRDN do in its last earnings report?
In its most recent report on Aug 6, 2026 (Q2 2026), Viridian Therapeutics, Inc. posted EPS of -$1.05 versus the -$1.03 estimate, a miss of 2.9%. Revenue was $233,000 against a $56,364 estimate. The stock's 1-day post-earnings move was +6.8%.
How much does VRDN stock move after earnings?
VRDN beat EPS estimates in 4 of its last 8 reported quarters. Over the last 8 reports the stock moved an average of 7.2% (up or down) in the day after earnings.
About Viridian Therapeutics, Inc.
Viridian Therapeutics, Inc. is a biotechnology firm committed to creating therapies for patients afflicted by serious illnesses. Its primary development efforts include VRDN-001, a humanized monoclonal anti-IGF-1R antibody currently advancing through Phase 1/2 clinical trials for thyroid eye disease (TED). The company's portfolio also features VRDN-002, an IGF-1R antibody undergoing Phase 1 clinical evaluation, alongside VRDN-003, a therapeutic antibody also designed to target IGF-1R for TED. Established in 2006, this Waltham, Massachusetts-based firm previously operated as Miragen Therapeutics, Inc., before changing its name to Viridian Therapeutics, Inc. in January 2021.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-06 | Q2 2026 | -1.03 | -1.05 | -2.94% | $233,000 | ❌ Miss | +6.83% | +8.59% | +8.97% |
| 2026-05-05 | Q1 2026 | -1.07 | -0.90 | +15.89% | $141,000 | ✅ Beat | +33.36% | +22.33% | +16.29% |
| 2026-02-26 | Q4 2025 | -0.96 | -1.08 | -12.50% | $132,000 | ❌ Miss | +1.90% | +5.01% | -2.56% |
| 2025-11-05 | Q3 2025 | -0.89 | -0.34 | +61.80% | $70,570 | ✅ Beat | +8.29% | +26.08% | +43.95% |
| 2025-08-06 | Q2 2025 | -0.98 | -1.00 | -2.04% | $75,000 | ❌ Miss | -1.38% | +3.04% | +6.88% |
| 2025-02-27 | Q4 2024 | -1.00 | -0.81 | +19.00% | $72,000 | ✅ Beat | +1.57% | +3.86% | -5.56% |
| 2024-05-08 | Q1 2024 | -1.10 | -0.79 | +28.18% | $72,000 | ✅ Beat | -1.59% | -3.10% | -19.22% |
| 2024-02-27 | Q4 2023 | -1.00 | -1.35 | -35.00% | $72,000 | ❌ Miss | +2.86% | -7.65% | -10.71% |
Showing last 8 quarters.
Revenue by segment & region
By segment
Q2 FY26 · $284K total
| Segment | Share | Revenue | YoY | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 |
|---|---|---|---|---|---|---|---|
| License | 82.0% | $233K | — | — | — | — | $70.0M |
| Collaboration | 18.0% | $51K | — | — | — | — | $570K |
Source: company filings via FMP. YoY compares the same fiscal period a year earlier.